Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters
Abstrakt
Rituximab (RTX) was reported effective in ANCA-associated vasculitis (AAV). We aimed to evaluate clinical efficacy of RTX in AAV along with its impact on immunological parameters.
Eighteen RTX-treated AAV patients (M/F 11/7; median age 37.5; 15x PR3-ANCA, 3x MPO-ANCA; 16x relapsing/refractory, 2x first-line therapy) were enrolled. Clinical response, ANCA, total serum IgG levels and cellular immunity parameters were examined.
The patients were followed up (FU) for a median of 26 months (range 3-82, 15 for a parts per thousand yen6 months). All patients achieved B cell depletion (lasting 3-24 months).
No significant increase was noted in T cell or NK cell subpopulations. At 6 months, partial remission was achieved in 5/15 patients (33 %) and complete in 8 (53 %).
The median prednisone dose (30..10 mg/d) and ANCA levels (17.2..2.7 IU/mL) decreased (p < 0.01). RTX retreatment was used in nine (8x pre-emptive, 1x relapse).
Six patients relapsed (none of the pre-emptively treated). Three patients died of infection.
IgG levels at 3 months decreased compared to baseline (9.0 vs 5.7 g/L, p < 0.01). Higher percentage of HLA-DR+CD3+ cells and lower percentage of CD4+CD45RA+ naive T cells persisted during FU.
IFN-gamma production increased at 6 months compared to baseline (27.3 vs 41.5 %). No significant change was noted in the intracellular IL-10 and IL-12 production.
RTX helped to lower the glucocorticosteroids dose and withdraw cytotoxic drugs in most AAV patients. Hypogammaglobulinaemia was common but well tolerated.
Peripheral circulating T cells remained activated despite B cell depletion.